Multisystem inflammatory syndrome in children (MIS-C) temporally associated with SARS-CoV-2 infection: a scoping review of the literature

Authors

Mohamed Sabbour^{1,*}, Seif Tarek El-Swaify^{1,*}, Nourhan Farrag^{1,*}, Menna Kamel^{1,*}, Sara H. Ali^{1,*}, Abdelrahman Amir^{1,*}, Mazen A. Refaat^{1,*}, Menatalla A. Dyab^{1,*}, Ashraf Nabhan^{2,3}

Affiliations

¹Faculty of Medicine, Ain Shams University, Cairo, Egypt

²Department of Obstetrics and Gynecology, Faculty of Medicine, Ain Shams University, Cairo, Egypt

³Egyptian Center for Evidence Based Medicine, Cairo, Egypt

*These authors contributed equally

ABSTRACT

Background: With the rise of the COVID-19 pandemic, a new severe life-threatening inflammatory syndrome has been reported in some pediatric populations. Global attention was shifted towards the syndrome termed multisystem inflammatory syndrome in children (MIS-C), with new case reports flooding in.

Objectives: The aim of this scoping review is to summarize the existing reports on MIS-C and focus on the demographics, diagnosis, clinical presentation, laboratory investigations, imaging studies, treatment, and patient outcomes.

Methods: We conducted a systemic search using LitCovid and MEDLINE electronic databases. We screened citations, titles and abstracts, then reviewed potentially relevant articles in full. After data extraction, we reported our final data under subheadings of demographics, diagnosis, clinical presentation, laboratory investigations, imaging studies, treatment, and patient outcomes.

Results: Our search strategy yielded 42 original studies reporting 674 pediatric patients fitting the case definition of MIS-C. The studies included 21 case reports, 16 case series and 5 cohort studies. The most common reported symptom of MIS-C was fever (98%). Gastrointestinal symptoms were common (N=557, 83%).

Interleukin-6 (IL-6) levels were measured in 125 patients and was elevated in 94 % (N=117). Echocardiography detected coronary artery lesions in 100 patients.

Prophylactic and/or therapeutic heparin was required in 34% (N=227) of patients.

The most commonly administered treatment modality targeting MIS-C was intravenous immunoglobulin (IVIG) (N=490). Corticosteroids (N=347) and aspirin (N=112) were also integral parts of the treatment regimens. Biologic therapy was integrated into the treatment regimen for 116 patients. Intensive care unit (ICU) admission was alarming (N=478, 71%). 9 fatalities were recorded due to MIS-C

Conclusions: We believe MIS-C bears pathophysiological resemblance to the well-known Kawasaki disease but with some key differences highlighted. Understanding those differences will aid our management plan for such patients.

INTRODUCTION

SARS-CoV-2 is widely considered to be the greatest infectious disease health threat of the 21st century. By the end of June 2020, COVID-19 had already affected more than 10 million people globally. So far, 3 people die every minute because of COVID-19 [1]. The case fatality ratio in adult patients has been reported to be between 1-3% [2]. Unfortunately, data pertaining to pediatric patients is less robust. In addition to lower reported case fatality ratios, pediatric patients appear to have mostly asymptomatic or mild infections [3,4].

Despite having a more favorable clinical course, a global state of vigilance has recently been called for when dealing with pediatric COVID-19 patients. In some of these patients, COVID-19 presented with a severe life-threatening inflammatory syndrome with multiple organ involvement [5]. This newly emerging disease entity was first reported by Jones et al. in May [6]. The yet unnamed syndrome caused confusion due to the overlapping clinical characteristics with Kawasaki disease and toxic shock syndrome. Consequently, the Centers for Disease Control and Prevention (CDC) and the Royal College of Paediatrics and Child Health (RCPCH) published case definitions and recommendations for physicians in managing multisystem inflammatory syndrome in children (MIS-C) [7,8].

These advisory statements have undoubtedly increased case detection. Additionally, as more clinical data is being published about MIS-C, physicians are becoming better at characterizing the syndrome. However, limitations in information still exist as regards the risk factors, pathogenesis, clinical course, and treatment for MIS-C.

The primary purpose of this scoping review is to reduce the knowledge gaps and help enable physicians to diagnose and make informed clinical decisions when caring for patients with MIS-C.

MATERIALS AND METHODS

We included primary studies coinciding with the 2020 COVID-19 pandemic of patients fulfilling the case definition of MIS-C as determined by the CDC [7]: An individual aged <21 years presenting with fever, laboratory evidence of inflammation, and evidence of clinically severe illness requiring hospitalization, with multisystem (>2) organ involvement (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic or neurological); AND no alternative plausible diagnoses; AND positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or antigen test; or exposure to a suspected or confirmed COVID-19 case within the 4 weeks prior to the onset of symptoms.

Our scoping review was designed based on the Arksey and O'Malley framework [9].

Stage 1: Identifying research questions

Our review of the recently emerging entity of MIS-C in COVID-19 was guided by the following questions; What are the demographics of MIS-C? How is SARS-CoV-2 infection confirmed? What is the clinical presentation of MIS-C? What are the laboratory and imaging characteristics of this disease? What are the possible management strategies? What is its prognosis?

Stage 2: Identifying relevant studies

We conducted a systematic search on LitCovid and MEDLINE electronic databases; the search was last updated on July 8, 2020. We did not impose any language restriction. Following study selection (stage 3), we hand-searched the reference list of the included studies and additional studies were retrieved. The detailed search strategy could be found in our supplementary material.

Stage 3: Study selection

Two authors (SH and NF) independently screened citations, titles and abstracts, then reviewed potentially relevant articles in full. This process was repeated independently by two other authors (MK and MS) and results were compared. We considered any article reporting original research on COVID-19 and MIS-C, hyperinflammatory syndrome, or Kawasaki-like illness, whether the diagnosis of COVID-19 was confirmed by RT-PCR, serology or based on clinical, imaging or even through epidemiological contact with confirmed cases. If agreement on abstract or full article inclusion could not be reached between the two reviewers, an opinion was requested from a third reviewer (SE)

A detailed flowchart of the study selection process can be found in figure 1.

Stage 4: Data charting process

A data-charting electronic form was jointly developed by two reviewers (MK and SE) to extract relevant variables. All authors independently extracted data and continuously updated the data-charting form. We extracted the following data items: general data (title, date of publication, authors' names, country); methodological data (sample size, participant characteristics - e.g. age, gender and ethnicity); and clinical

data (method of COVID-19 confirmation, clinical presentation, laboratory and imaging findings, treatment(s) administered, patient outcomes). As this is a scoping review, we did not perform a formal critical appraisal of primary studies.

Stage 5: Summarizing results

The results were reported under the following categories: demographics, diagnosis, clinical presentation, laboratory investigations, imaging studies, treatment, and patient outcomes.

We reported the review following the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines-extension for scoping review [10].

RESULTS

Our search strategy yielded 42 original studies reporting 674 pediatric patients fitting the case definition of MIS-C. All studies were published in 2020. Figure 1 shows the study inclusion process in this scoping review. The studies included 21 case reports, 16 case series and 5 cohort studies. The distribution of study designs included in the review are summarized in Table 1.

We included studies from the following countries: 19 from the USA [6,11-28], 7 from the UK [29-35], 6 from France [36-41], 3 from Italy [42-44], 2 from both India [45,46] and Switzerland [47,48], and 1 from each of Luxembourg [49], Israel [50], and Turkey [51]. The records of 8 patients were removed twice because of duplication in 3 studies [31,34,35].

Demographics

Our study population had a mean age of 8.9 years. There was a slight male predilection (N=381 males vs 292 females). One child did not have their gender specified. The highest reported ethnicity was Afro-Caribbean (25%). Other minor reported ethnicities included ten mixed, three Indian, and two Middle Eastern patients. Out of the total number of patients, 135 were overweight/obese and 95 patients had pre-existing comorbidities: 47 had an unspecified respiratory condition, 23 had bronchial asthma, 11 had autoimmune disease, 7 had cardiac disease, and 7 had other conditions. The demographics are summarized in Table 2.

Diagnosis

The majority of patients (N=665) underwent reverse transcription-polymerase chain reaction (RT-PCR) testing. RT-PCR had a confirmatory yield of 39% (N=258). Five-hundred and thirty three patients underwent serological testing. It had a confirmatory yield of 86% (N=457). Around 8% of the patient population (N=57) were negative using both testing modalities. Notably, 175 patients had a positive epidemiologic link to a known COVID-19 case. Table 3 shows the results of confirmatory testing.

Clinical Presentation

The most common reported symptom of MIS-C was fever (98%) lasting between 1 to 19 days. Gastrointestinal symptoms –diarrhea, abdominal pain, and vomiting- were

particularly common (N=557, 83%). Furthermore, 98 patients (15%) presented with cervical, mesenteric or mediastinal lymphadenopathy. A few cases reported the following symptoms: edema (N=42), hepatitis (N=26), arthralgia (N=12) and epididymo-orchitis (N=4). Table 4 illustrates the frequency of other clinical features among patients.

Laboratory Investigations

Patients predominantly demonstrated laboratory findings consistent with an acute inflammatory response including neutrophilia (50%), elevated CRP (78%) and hypoalbuminemia (52%). 125 patients had their interleukin-6 (IL-6) levels measured, it was elevated in 94 % (N=117). Additionally, five patients fulfilled the diagnostic criteria for macrophage activation syndrome.

Myocardial involvement was indicated by elevated troponin levels (55%), and elevated lipase was reported in 11 patients. The laboratory findings are demonstrated in Table 5.

Other hematologic findings reported included lymphocytosis (N=7) and coagulopathy, which was uncommonly reported, with elevated PT (N=27) and elevated aPTT (N=6).

Imaging Studies

Only 325 patients underwent chest imaging during the course of their illness. Out of these patients, 192 of them demonstrated features of atypical pneumonia in the form

of either localized opacities (shadows/nodules) (N=75), ground glass opacities (N=14) or lobar consolidation mainly in the lower and posterior lobes (N=72). Pleural effusion was also noted in 93 patients. Echocardiography detected coronary artery lesions in 100 patients. These lesions were either coronary dilatation (N=40) or coronary aneurysm (N=60). In addition, electrocardiography was performed for 20% of patients. The most common finding was sinus tachycardia. Pelviabdominal imaging (CT and U/S) revealed ascites (N=25) and ileocolitis (N=10) in some patients. Table 6 outlines the imaging modalities and findings reported.

Treatment

Treatment modalities included supportive measures for the COVID-19 illness in addition to specific measures directed to the MIS-C. The major treatment modalities are represented in figure 2. Prophylactic and/or therapeutic heparin was required in 34 % (N=227) of patients. Supplemental oxygen therapy was required in just 16% of patients. Few patients received medications targeting the causative COVID-19 viral illness. Only 7 patients received hydroxychloroquine and 4 received remdesivir. On the other hand, antibiotics, mainly 3rd generation cephalosporins, were used in 169 patients.

The most commonly administered treatment modality targeting MIS-C was intravenous immunoglobulin (IVIG) (N=490). IVIG resistance was encountered in 11% (N=73) of these patients. Corticosteroids (N=347) and aspirin (N=112) were also integral parts of the treatment regimens. Biologic therapy was integrated into the

treatment regimen for 116 patients including anakinra (N=56), infliximab (N=9), and tocilizumab (N=52). Only 2 patients received convalescent plasma.

Patient Outcomes

Multiorgan system disease was reported in the majority of our included studies. Many patients presenting with MIS-C required intensive care unit (ICU) admission (N=478, 71%). The length of ICU stay ranged from 1 to 46 days with a median of 6 days. The most common reported cause for ICU admission was hemodynamic instability necessitating vasopressor and inotropic support.

Patients required organ support in the form of vasopressors and inotropes (N=377, 56%), invasive mechanical ventilation (N=152, 23%), extracorporeal membrane oxygenation (ECMO) (N=30, 4%), and renal replacement therapy (N=9, 1%). Acalcular cholecystitis was observed in 6 patients. Despite the severity of disease, only 9 fatalities were recorded due to MIS-C; four were due to neurologic events.

DISCUSSION

A consistent understanding of MIS-C temporally associated with SARS-CoV-2 infection is forming, and the distinction from Kawasaki disease (KD) is emerging. Our scoping review describes the clinical profiles of 674 pediatric patients who met the criteria for this syndrome. Cases have been reported worldwide from over nine countries. Despite underreporting of ethnicities, with around 70% (N=475) of cases

having a reported ethnicity, Afro-Caribbean and Hispanic ethnicities constituted around half of all cases. This pattern was consistent with findings reported by Feldstein et al. [26]. The mean age was 8.9 years and there was a slight male gender predilection. Conversely, KD tends to affect Asian children younger than 5 years with a similar slight male predominance [52,53]. The presence of comorbidities correlates with severe COVID-19 illness in adults [54]. This correlation may also be consistent with developing MIS-C; 14% of affected children had an underlying illness. However, only 20% had an elevated body mass index which is close to the worldwide prevalence of this condition.

Ecological time-period analyses have verified an association between the sudden rise of Kawasaki-like disease, later termed MIS-C, and the rise of SARS-CoV-2 circulation in a population [25,55]. In fact, Verdoni et al. reported a 30-fold increased incidence of Kawasaki-like disease [43]. Serological testing had a higher confirmatory yield of COVID-19 status (86%) in contrast with RT-PCR (39%). Current understanding of the pathogenesis of this syndrome is that it is a post-infectious sequela triggered by an immune-mediated injury. This may help explain why viral particles are not detected in the majority of patients.

The multiorgan involvement characterizing MIS-C was most frequently manifested by fever (98%), gastrointestinal symptoms (83%) and skin rash (55%). Even though the range of fever spanned 1 to 19 days, we noticed that most patients had a fever duration of 8 days or less. Although clinical signs suggestive of KD -skin rash, mucocutaneous inflammation and cervical lymphadenopathy- were frequent, most patients only fulfilled the criteria for incomplete KD [37,40]. Gastrointestinal symptoms

were particularly common (83%) in MIS-C. This is in stark contrast with KD which has a lower rate of gastrointestinal involvement [56,57].

Acute kidney injury (AKI) was one of the presenting features in around 16% of patients. Fortunately, only 1% of patients required renal replacement therapy. The incidence of AKI is comparatively low in patients with KD and only a minority require some form of dialysis [58]. Almost one-fifth of patients reported neurological symptoms. Most of these symptoms were minor but Abdel-Mannan et al. suggested that there may be a high incidence of underlying brain MRI signal changes [29].

A hyperinflammatory shock state induced by inflammatory cytokines, which are integral to the pathogenesis of SARS-CoV-2 infection, was typified by 43% and 49% of patients presenting with hypotension and cardiac symptoms, respectively. Most of these patients eventually required vasopressor and/or inotropic support (56%). In contrast, approximately 5% of children with KD in the United States present with cardiovascular collapse and hypotension requiring vasopressor and/or inotropic support [59]. Another interesting finding was that in spite of 49% of patients having initial presentation suggestive of cardiac affection, 55% and 80% eventually developed laboratory and echocardiographic evidence of cardiac pathology during hospitalization, respectively.

Coronary artery abnormalities, an important complication of KD, have been reported in 18% of those who underwent echocardiography. However, only 11% (N=60) of patients developed coronary artery aneurysms (CAA) as opposed to the proposed 25% incidence of CAA in patients with KD [60]. MIS-C patients who developed CAA

were generally older and had higher levels of inflammatory cardiac markers when compared to historical KD cohorts [34].

We observed a laboratory pattern highlighting the underlying cytokine storm with elevated CRP, neutrophilia, elevated d-dimer, lymphopenia, and elevated ferritin [61]. When compared to historical cohorts of KD, MIS-C patients were more likely to have neutrophilia, lymphopenia, anemia, elevated CRP, and ferritin [38,34,43]. They also tended to have higher troponin and BNP levels but lower platelet counts. In addition, macrophage activation syndrome, a form of cytokine storm, was reported in 5 patients. Given its role as a marker of severity of COVID-19 illness, hypoalbuminemia was predictably present in 52% of patients [62]. Although data has been published on the use of IL-6 as a prognostic marker in COVID-19, only 19% (N=125) of MIS-C patients underwent interleukin testing [63].

According to the American Heart Association (AHA) guidelines on the treatment of KD, a single infusion of IVIG (2g/kg) should be administered along with aspirin until the patient is afebrile. The addition of glucocorticoids was suggested only for patients at high risk of developing coronary artery aneurysms [64]. However, most centers treating MIS-C cases considered them to be high risk patients, and therefore administered IVIG, aspirin and pulse steroids concurrently. The incidence of IVIG resistance (11%) was similar to the reported rates for KD. Biologic therapy (e.g. anti-IL-6, anti-TNF, etc..) was used independently of IVIG resistance sometimes with the initial regimen on admission. This treatment decision may have been influenced by recent experience with these drugs in adult COVID-19 patients.

Almost a third of MIS-C patients required prophylactic/therapeutic anticoagulation. None of the included studies reported coronary occlusion which is the main indication for anticoagulation in KD [64]. In fact, most studies did not list their indications for anticoagulation. However, it is logical to infer that some of these patients were at particularly high risk of venous thromboembolism given these risk factors: multi-organ system involvement, markedly elevated d-dimers and inflammatory markers, pediatric ICU admission, and the prothrombotic effect of the SARS-CoV-2 infection itself [65].

We found that a significant number of patients required ICU admission (71%). This alarming rate is much higher than rates reported for KD (3%) [66,67]. The benefits of ECMO in adults with COVID-19 are controversial due to the associated risk of thromboembolism especially in those with cytokine storm syndrome [68]. We observed a similar association in our study population; 30 patients ultimately required ECMO, and 7 of them died including 3 by acute neurologic events. However, this association may be confounded by the deteriorating physiological parameters that ultimately led to the need for ECMO.

Our study had several limitations. The first and foremost is that we did not assess the quality of reports. We understand that during a pandemic, the intention to share data rapidly might have an impact on the quality of published primary reports. Some of the primary sources might overlap. We have traced the cases through careful data collection and contacting the authors to minimize the possibility of double counting. Another limitation is that the included studies used variable methods of reporting. We contacted several study authors to obtain primary data and reduce inter-study

variability. Several studies had incomplete data for their patients. We understand this may introduce bias in the reporting of certain variables such as mortality. Finally, most studies did not report the exact confirmatory method for diagnosing MIS-C, whether RT-PCR or serology, on an individual basis. We also selected patients according to the CDC case definition only.

In conclusion, we believe MIS-C bears pathophysiological resemblance to the well-known Kawasaki disease. In fact, respiratory viruses, including coronaviridae, have also been implicated in the etio-pathogenesis of KD [69-71]. This review summarizes the major points of difference between both entities. The predominant hyperinflammatory features, the delayed onset after SARS-CoV-2 infection, and the similarity to KD support the hypothesis that MIS-C is a syndrome of immune-mediated injury [72]. This proinflammatory effect of SARS-CoV-2 has also been reported in individuals with severe COVID-19 illness [73,74]. We recommend that future studies are designed to outline prognostic variables and effective treatment strategies. There is still insufficient data to guide cardiac follow-up for MIS-C patients. The use of serological titers for risk stratification is another potential research question [75].

Acknowledgement

We thank Dr. Mostafa El-Hodhod (Prof of Pediatrics. Faculty of Medicine. Ain shams University) for his assistance and his expert opinion on the subject. We thank Mohamed Elshebiny and Farida Elshafeey for their valued contribution to this paper.

Conflict of Interest

All authors have nothing to disclose

Funding

None

REFERENCES

1. World Health Organization. Coronavirus disease 2019 (COVID-19): Situation Report – 129. 28 May 2020. Accessed at www.who.int/docs/default-source/coronaviruse/20200630-covid-19-sitrep-162.pdf?sfvrsn=e00a5466_2
2. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. *The Lancet Infectious Diseases*. 2020 Mar; doi: 10.1016/S1473-3099(20)30243-7.
3. Castagnoli R, Votto M, Licari A, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review. *JAMA Pediatr*. 2020 Apr 22.
4. CDC COVID-19 Response Team. Coronavirus disease 2019 in children - United States, February 12-April 2, 2020. *MMWR Morb Mortal Wkly Rep*. 2020 Apr 10. 69 (14):422-6.
5. Mahase E. Covid-19: concerns grow over inflammatory syndrome emerging in children. *BMJ*. 2020;369.

6. Jones VG, Mills M, Suarez D, et al. COVID-19 and Kawasaki disease: novel virus and novel case. *Hosp Pediatr*. 2020; doi: 10.1542/hpeds.2020-0123.
7. CDC. Multisystem Inflammatory Syndrome in Children (MIS-C) associated with coronavirus disease 2019 (COVID-19).
<https://emergency.cdc.gov/han/2020/han00432.asp>
8. Royal College of Paediatrics and Child Health Guidance: Paediatric multisystem inflammatory syndrome temporally associated with COVID-19. 2020.
<https://www.rcpch.ac.uk/sites/default/files/2020-05/COVID-19-Paediatric-multisystem-%20inflammatory%20syndrome-20200501.pdf>
9. Arksey H, O'Malley L. Scoping studies: Towards a methodological framework. *Int J Soc Res Methodol*. 2005;8:19–32.
10. Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation. *Ann Intern Med*. 2018;169:467–473.
11. Cheung EW, Zachariah P, Gorelik M, et al. Multisystem Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and Adolescents in New York City [published online ahead of print, 2020 Jun 8]. *JAMA*. 2020;e2010374. doi:10.1001/jama.2020.10374
12. Miller J, Cantor A, Zachariah P, Ahn D, Martinez M, Margolis K. Gastrointestinal symptoms as a major presentation component of a novel multisystem inflammatory syndrome in children (MIS-C) that is related to COVID-19: a single center experience of 44 cases [published online ahead of print, 2020 Jun 4]. *Gastroenterology*. 2020;S0016-5085(20)34753-3. doi:10.1053/j.gastro.2020.05.079

13. Chiu JS, Lahoud-Rahme M, Schaffer D, Cohen A, Samuels-Kalow M, Kawasaki Disease Features and Myocarditis in a Patient with COVID-19 [published online ahead of print, 2020 Jun 15]. *Pediatr Cardiol.* 2020;1-3. doi:10.1007/s00246-020-02393-0
14. Greene AG, Saleh M, Roseman E, Sinert R. Toxic shock-like syndrome and COVID-19: A case report of multisystem inflammatory syndrome in children (MIS-C) [published online ahead of print, 2020 Jun 6]. *Am J Emerg Med.* 2020;S0735-6757(20)30492-7. doi:10.1016/j.ajem.2020.05.117
15. Patel PA, Chandrakasan S, Mickells GE, Yildirim I, Kao CM, Bennett CM. Severe Pediatric COVID-19 Presenting With Respiratory Failure and Severe Thrombocytopenia [published online ahead of print, 2020 May 4]. *Pediatrics.* 2020;e20201437. doi:10.1542/peds.2020-1437
16. Latimer G, Corriveau C, DeBiasi RL, et al. Cardiac dysfunction and thrombocytopenia-associated multiple organ failure inflammation phenotype in a severe paediatric case of COVID-19. *Lancet Child Adolesc Health.* 2020;4(7):552-554. doi:10.1016/S2352-4642(20)30163-2
17. Waltuch T, Gill P, Zinns LE, et al. Features of COVID-19 post-infectious cytokine release syndrome in children presenting to the emergency department [published online ahead of print, 2020 May 23]. *Am J Emerg Med.* 2020;S0735-6757(20)30403-4. doi:10.1016/j.ajem.2020.05.058
18. Chiotos K, Bassiri H, Behrens EM, et al. Multisystem Inflammatory Syndrome in Children during the COVID-19 pandemic: a case series [published online ahead of print, 2020 May 28]. *J Pediatric Infect Dis Soc.* 2020;piaa069. doi:10.1093/jpids/piaa069

19. Deza Leon MP, Redzepi A, McGrath E, et al. COVID-19 Associated Pediatric Multi-System Inflammatory Syndrome [published online ahead of print, 2020 May 22]. J Pediatric Infect Dis Soc. 2020;piaa061. doi:10.1093/jpids/piaa061
20. Dolinger MT, Person H, Smith R, et al. Pediatric Crohn's Disease and Multisystem Inflammatory Syndrome in Children (MIS-C) and COVID-19 Treated with Infliximab [published online ahead of print, 2020 May 22]. J Pediatric Gastroenterol Nutr. 2020;10.1097/MPG.0000000000002809. doi:10.1097/MPG.0000000000002809
21. Rivera-Figueroa EI, Santos R, Simpson S, Garg P. Incomplete Kawasaki Disease in a Child with Covid-19 [published online ahead of print, 2020 May 9]. Indian Pediatr. 2020;S097475591600179.
22. DeBiasi RL, Song X, Delaney M, et al. Severe COVID-19 in Children and Young Adults in the Washington, DC Metropolitan Region [published online ahead of print, 2020 May 13]. J Pediatr. 2020;10.1016/j.jpeds.2020.05.007. doi:10.1016/j.jpeds.2020.05.007.
23. Capone CA, Subramony A, Sweberg T, Schneider J, Shah S, Rubin L, Schleien C, the Northwell Health COVID-19 Research Consortium, Epstein S, Johnson JC, Kessel A, Misra N, Mitchell E, Palumbo N, Rajan S, Rocker J, Williamson K, Davidson KW. Characteristics, Cardiac involvement, and Outcomes of Multisystem Inflammatory Disease of Childhood (MIS-C) Associated with SARS-CoV-2 Infection. The Journal of Pediatrics (2020). <https://doi.org/10.1016/j.jpeds.2020.06.044>.

24. Dasgupta K, Finch SE. A Case of Pediatric Multisystem Inflammatory Syndrome Temporally Associated with COVID-19 in South Dakota. *S D Med.* 2020;73(6):246-251.
25. Dufort EM, Koumans EH, Chow EJ, et al. Multisystem Inflammatory Syndrome in Children in New York State [published online ahead of print, 2020 Jun 29]. *N Engl J Med.* 2020;NEJMoa2021756. doi:10.1056/NEJMoa2021756.
26. Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents [published online ahead of print, 2020 Jun 29]. *N Engl J Med.* 2020;NEJMoa2021680. doi:10.1056/NEJMoa2021680.
27. Kaushik S, Aydin SI, Derespina KR, Bansal PB, Kowalsky S, Trachtman R, Gillen JK, Perez MM, Soshnick SH, Conway Jr. EE, Bercow A, Seiden HS, Pass RH, Ushay HM, Ofori-Amanfo G, Medar SS. Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARSCoV-2 Infection: A Multi-institutional Study from New York City. *The Journal of Pediatrics* (2020).
<https://doi.org/10.1016/j.jpeds.2020.06.045>.
28. Riollano-Cruz M, Akkoyun E, Briceno-Brito E, et al. Multisystem Inflammatory Syndrome in Children (MIS-C) Related to COVID-19: A New York City Experience [published online ahead of print, 2020 Jun 25]. *J Med Virol.* 2020;10.1002/jmv.26224. doi:10.1002/jmv.26224
29. Abdel-Mannan O, Eyre M, Löbel U, et al. Neurologic and Radiographic Findings Associated With COVID-19 Infection in Children. *JAMA Neurol.* Published online July 01, 2020. doi:10.1001/jamaneurol.2020.2687.
30. Ng KF, Kothari T, Bandi S, et al. COVID-19 multisystem inflammatory syndrome in three teenagers with confirmed SARS-CoV-2 infection [published online ahead

of print, 2020 Jun 22]. J Med Virol. 2020;10.1002/jmv.26206.

doi:10.1002/jmv.26206.

31. Hameed S, Elbaaly H, Reid CEL, et al. Spectrum of Imaging Findings on Chest Radiographs, US, CT, and MRI Images in Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19 [published online ahead of print, 2020 Jun 25]. Radiology. 2020;202543. doi:10.1148/radiol.2020202543.
32. Pain CE, Felsenstein S, Cleary G, et al. Novel paediatric presentation of COVID-19 with ARDS and cytokine storm syndrome without respiratory symptoms [published online ahead of print, 2020 May 15]. Lancet Rheumatol. 2020;10.1016/S2665-9913(20)30137-5. doi:10.1016/S2665-9913(20)30137-5
33. Ramcharan T, Nolan O, Lai CY, et al. Paediatric Inflammatory Multisystem Syndrome: Temporally Associated with SARS-CoV-2 (PIMS-TS): Cardiac Features, Management and Short-Term Outcomes at a UK Tertiary Paediatric Hospital [published online ahead of print, 2020 Jun 12]. Pediatr Cardiol. 2020;1-11. doi:10.1007/s00246-020-02391-2
34. Whittaker E, Bamford A, Kenny J, et al. Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2 [published online ahead of print, 2020 Jun 8]. JAMA. 2020;e2010369. doi:10.1001/jama.2020.10369
35. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;395(10237):1607-1608. doi:10.1016/S0140-6736(20)31094-1
36. Blondiaux E, Parisot P, Redheuil A, et al. Cardiac MRI of Children with Multisystem Inflammatory Syndrome (MIS-C) Associated with COVID-19: Case

Series [published online ahead of print, 2020 Jun 9]. Radiology. 2020;202288.

doi:10.1148/radiol.2020202288.

37. Grimaud M, Starck J, Levy M, et al. Acute myocarditis and multisystem inflammatory emerging disease following SARS-CoV-2 infection in critically ill children. Ann Intensive Care. 2020;10(1):69. Published 2020 Jun 1.
doi:10.1186/s13613-020-00690-8
38. Pouletty M, Borocco C, Ouldali N, et al. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort [published online ahead of print, 2020 Jun 11]. Ann Rheum Dis. 2020;annrheumdis-2020-217960.
doi:10.1136/annrheumdis-2020-217960
39. Toubiana J, Poirault C, Corsia A, et al. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. BMJ. 2020;369:m2094. Published 2020 Jun 3.
doi:10.1136/bmj.m2094.
40. Belhadjer Z, Méot M, Bajolle F, et al. Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic [published online ahead of print, 2020 May 17]. Circulation. 2020;10.1161/CIRCULATIONAHA.120.048360.
doi:10.1161/CIRCULATIONAHA.120.048360
41. Labé P, Ly A, Sin C, et al. Erythema multiforme and Kawasaki disease associated with COVID-19 infection in children [published online ahead of print, 2020 May 26]. J Eur Acad Dermatol Venereol. 2020;10.1111/jdv.16666.
doi:10.1111/jdv.16666

42. Giacometti V, Manfredini VA, Meraviglia G, et al. Acute Inflammation and Elevated Cardiac Markers in a Two-Month-Old Infant with Severe Acute Respiratory Syndrome Coronavirus 2 Infection Presenting with Cardiac Symptoms. *Pediatric Infect Dis J*. 2020;39(7):e149-e151. doi:10.1097/INF.0000000000002750
43. Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. *Lancet*. 2020;395(10239):1771-1778. doi:10.1016/S0140-6736(20)31103-X.
44. Licciardi F, Pruccoli G, Denina M, et al. SARS-CoV-2-Induced Kawasaki-Like Hyperinflammatory Syndrome: A Novel COVID Phenotype in Children [published online ahead of print, 2020 May 21]. *Pediatrics*. 2020;e20201711. doi:10.1542/peds.2020-1711
45. Rauf A, Vijayan A, John ST, Krishnan R, Latheef A. Multisystem Inflammatory Syndrome with Features of Atypical Kawasaki Disease during COVID-19 Pandemic [published online ahead of print, 2020 May 28]. *Indian J Pediatr*. 2020;10.1007/s12098-020-03357-1. doi:10.1007/s12098-020-03357-1
46. Acharyya BC, Acharyya S, Das D. Novel Coronavirus Mimicking Kawasaki Disease in an Infant [published online ahead of print, 2020 May 22]. *Indian Pediatr*. 2020;S097475591600184.
47. Dallan C, Romano F, Siebert J, Politi S, Lacroix L, Sahyoun C. Septic shock presentation in adolescents with COVID-19. *Lancet Child Adolesc Health*. 2020;4(7):e21-e23. doi:10.1016/S2352-4642(20)30164-4.
48. Bapst, Thomas & Romano, Fabrizio & Müller, Marie & Rohr, Marie. (2020). Special dermatological presentation of paediatric multisystem inflammatory

- syndrome related to COVID-19: erythema multiforme. *BMJ Case Reports*. 13. e236986. 10.1136/bcr-2020-236986.
49. Oberweis ML, Codreanu A, Boehm W, et al. Pediatric Life-Threatening Coronavirus Disease 2019 With Myocarditis. *Pediatr Infect Dis J*. 2020;39(7):e147-e149. doi:10.1097/INF.0000000000002744
50. Schnapp A, Abulhija H, Maly A, et al. Introductory histopathologic findings may shed light on COVID19 pediatric hyperinflammatory shock syndrome [published online ahead of print, 2020 Jun 13]. *J Eur Acad Dermatol Venereol*. 2020;10.1111/jdv.16749.
51. Yozgat CY, Uzuner S, Bursal Duramaz B, et al. Dermatological manifestation of pediatrics multisystem inflammatory syndrome associated with COVID-19 in a 3-year-old girl [published online ahead of print, 2020 Jun 4]. *Dermatol Ther*. 2020;e13770. doi:10.1111/dth.13770.
52. Uehara R., Belay E.D. Epidemiology of Kawasaki disease in Asia, Europe, and the United States. *J. Epidemiol*. 2012;22:79–85. doi: 10.2188/jea.JE20110131.
53. Pinna GS, Kafetzis DA, Tselkas OI, Skevaki CL. Kawasaki disease: an overview. *Curr Opin Infect Dis*. 2008 Jun. 21(3):263-70.
54. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA*. 2020;323(20):2052–2059. doi:10.1001/jama.2020.6775
55. Ouldali N, Pouletty M, Mariani P, et al. Emergence of Kawasaki disease related to SARS-CoV-2 infection in an epicentre of the French COVID-19 epidemic: a

time-series analysis. Lancet Child Adolesc Health 2020; published online July 2.

[https://doi.org/10.1016/S2352-4642\(20\)30175-9](https://doi.org/10.1016/S2352-4642(20)30175-9).

56. Miyake T, Kawamori J, Yoshida T, Nakano H, Kohno S, Ohba S. Small bowel pseudo-obstruction in Kawasaki disease. *Pediatr Radiol*. 1987;17(5):383-386.
doi:10.1007/BF02396613

57. Zulian F, Falcini F, Zancan L, et al. Acute surgical abdomen as presenting manifestation of Kawasaki disease. *J Pediatr*. 2003;142(6):731-735.
doi:10.1067/mpd.2003.232.

58. Watanabe, Toru. Clinical features of acute kidney injury in patients with Kawasaki disease. *World journal of clinical pediatrics* vol. 7,3 83-88. 30 Aug. 2018,
doi:10.5409/wjcp.v7.i3.83

59. McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. *Circulation* 2017;135(17):e927-e999.

60. Kato H, Sugimura T, Akagi T, et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. *Circulation*. 1996;94(6):1379-1385. doi:10.1161/01.cir.94.6.1379.

61. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet* 2020; 395: 1033–34.

62. Aziz M, Fatima R, Lee-Smith W, Assaly R. The association of low serum albumin level with severe COVID-19: a systematic review and meta-analysis. Crit Care. 2020;24(1):255. Published 2020 May 26. doi:10.1186/s13054-020-02995-3
63. Aziz M, Fatima R, Assaly R. Elevated interleukin-6 and severe COVID-19: a meta-analysis. J Med Virol. 2020. 10.1002/jmv.25948.
64. McCrindle, Brian W. et al. Diagnosis, Treatment, And Long-Term Management Of Kawasaki Disease: A Scientific Statement For Health Professionals From The American Heart Association. Circulation, vol 135, no. 17, 2017. Ovid Technologies (Wolters Kluwer Health), doi:10.1161/cir.0000000000000484.
65. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417-1418. doi:10.1016/S0140-6736(20)30937-5.
66. Kuo, Ching-Chia et al. Characteristics of children with Kawasaki disease requiring intensive care: 10 years' experience at a tertiary pediatric hospital. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi vol. 51,2 (2018): 184-190. doi:10.1016/j.jmii.2016.06.004.
67. Dominguez, Samuel R et al. Kawasaki disease in a pediatric intensive care unit: a case-control study. Pediatrics vol. 122,4 (2008): e786-90. doi:10.1542/peds.2008-1275.
68. Beyls, Christophe et al. Extracorporeal membrane oxygenation for COVID-19-associated severe acute respiratory distress syndrome and risk of thrombosis. British journal of anaesthesia, S0007-0912(20)30324-X. 4 May. 2020, doi:10.1016/j.bja.2020.04.079.

69. Turnier JL, Anderson MS, Heizer HR, Jone PN, Glodé MP, Dominguez SR.
Concurrent Respiratory Viruses and Kawasaki Disease. Pediatrics.
2015;136(3):e609-e614. doi:10.1542/peds.2015-0950.
70. Esper F, Shapiro ED, Weibel C, Ferguson D, Landry ML, Kahn JS. Association
between a novel human coronavirus and Kawasaki disease. J Infect Dis 2005;
191: 499–502.
71. Shirato K, Imada Y, Kawase M, Nakagaki K, Matsuyama S, Taguchi F. Possible
involvement of infection with human coronavirus 229E, but not NL63, in Kawasaki
disease. J Med Virol 2014; 86: 2146–53.
72. Carter, M.; Fish, M.; Jennings, A.; Doores, K.J.; Wellman, P.; Seow, J.; Acors, S.;
Timms, E.; Kenny, J.; Neil, S.; H. Malim, M.; Tibby, S.M.; Shankar-Hari, M.
Immunophenotyping of Circulating Leukocytes Reveal Non-specific Activation of
Innate and Adaptive Immune Systems in Multi-System Inflammatory Syndrome of
Childhood Temporally Associated with SARS-Cov-2 Infection: Descriptive Cohort
Study. Preprints 2020, 2020070252 (doi: 10.20944/preprints202007.0252.v1).
73. McGonagle D, Sharif K, O'Regan A, Bridgewood C. The role of cytokines
including interleukin-6 in COVID-19 induced pneumonia and macrophage
activation syndrome-like disease. Autoimmun Rev 2020; published online April 3.
DOI:10.1016/j.autrev.2020.102537.
74. Molloy EJ, Bearer CF. COVID-19 in children and altered inflammatory responses.
Pediatr Res 2020; published online April 3. DOI:10.1038/s41390-020-0881-y.
75. Christina A. Rostad, Ann Chahroudi, Grace Mantus et al. Serology in Children
with Multisystem Inflammatory Syndrome (MIS-C) associated with COVID-19.

medRxiv 2020.07.10.20150755; doi:

<https://doi.org/10.1101/2020.07.10.20150755>.